Real-World outcomes in COPD patients starting Trixeo (budesonide/glycopyrronium/formoterol) in Spain. - ORESTES

Study identifier:D5980R00096

ClinicalTrials.gov identifier:NCT06321731

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Observational Retrospective Study To Describe Characteristics And Evaluate Real-World Outcomes in COPD Patients Initiating Trixeo Aerosphere (budesonide/glycopyrronium bromide/formoterol fumarate) in Spain

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

500

Study type

Observational

Age

40 Years - 130 Years

Date

Study Start Date: 02 Jul 2024
Estimated Primary Completion Date: 30 Nov 2024
Estimated Study Completion Date: 30 Nov 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria